Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences

The world's first CRISPRenabled platform for disease detection.
Type
B2b
Founded
2017
Raised
$218M
Follow us
Featured on
Alexa global traffic share
Twitter followers
Latest funding Show all
$150,000,000
Venture capital (Series D) - 2021
Redmile Group Greenspring Associates Mayfield Fund +6
$45,000,000
Venture capital (Series B) - 2020
Mayfield Fund Decheng Capital Plum Alley +6
Team Size
1–10
Employees
Forbes Tech

What Drives Newly Minted CRISPR Unicorn Mammoth Biosciences

$150,000,000 Venture capital (Series D)
TechCrunch , Forbes Tech , MedCity News

Breakout “CRISPR platform” company Mammoth Biosciences is officially a unicorn

Forbes Tech

Mammoth Biosciences Signs Exclusive Deal For Recently-Discovered Crispr Protein

TechCrunch

Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH fundings through RADx program

TechCrunch

Mammoth Biosciences receives first peer-reviewed validation of CRISPR-based COVID-19 test

$45,000,000 Venture capital (Series B)
FinSMEs , MedCity News

Mammoth Biosciences Raises $45M in Series B Funding Round

TechCrunch

Mammoth Biosciences aims to be Illumina for the gene editing generation

$23,000,000 Venture capital (Series A)
FinSMEs , PE HUB

CRISPR-Based Disease Detection Platform Mammoth Biosciences Raises $23M

Funding
TechCrunch

Mammoth Biosciences raises $23 million for its CRISPR-based disease detection engine

Science Funding
TechCrunch

Mammoth Biosciences launches a CRISPR-powered search engine for disease detection

Science